Skip to main content
TG THERAPEUTICS, INC. logo

TG THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · TGTX ISIN · US88322Q1085 LEI · 529900X21UKABN9NJ529 US Manufacturing
Open in API
Filings indexed 1,012 across all filing types
Latest filing 2018-04-24 Regulatory Filings
Country US United States of America
Listing US TGTX

About TG THERAPEUTICS, INC.

https://www.tgtherapeutics.com/

TG Therapeutics, Inc. is a fully integrated, commercial-stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. The company's primary area of focus is autoimmune diseases, particularly multiple sclerosis (MS). Its lead commercial product is BRIUMVI® (ublituximab), an approved therapy for adults with relapsing forms of MS. TG Therapeutics also develops a pipeline of potential therapies for B-cell malignancies and other autoimmune conditions, including investigational CAR-T cell therapies.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text indicates it is reporting "Other Events" related to a press release about clinical trial results. It does not contain financial statements or detailed financial data, nor is it an annual or quarterly report. The document is short (2792 characters) and primarily serves as a notification of an event and includes a press release as an exhibit. Therefore, it fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous filings that do not fit other categories.
2018-04-24 English
10-K
Annual Report FY 2017
2018-03-15 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 8, 2018, reporting the results of operations for the fourth quarter and year ended December 31, 2017. It mentions a press release announcing financial results and an upcoming investor conference call. The document itself is short (2879 characters) and primarily serves to announce the earnings release and the conference call, with the press release attached as an exhibit. There are no detailed financial statements or substantive financial data within this document itself. According to the 'Menu vs Meal' rule, this is an announcement of an earnings release rather than the earnings release report itself. Therefore, the appropriate classification is Earnings Release (ER).
2018-03-08 English
13G/A
Major Shareholding Notification
2018-02-14 English
Major Shareholding Notification 2018
Major Shareholding Notification
2018-02-13 English
V020218_8K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text mentions a press release about clinical trial results presented at a conference, and the press release is filed as an exhibit. The document length is 2860 characters, which is short and primarily serves as an announcement rather than a detailed report. There are no financial statements or detailed financial data included. The content fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit into more specific categories like Earnings Release or Annual Report.
2018-02-02 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.